A COST-UTILITY ANALYSIS OF TWO TRABECULAR MICRO-BYPASS STENTS IN PATIENTS WITH MILD-TO-MODERATE OPEN-ANGLE GLAUCOMA IN FRANCE

Author(s)

Nieland K1, Kleintjens J1, Gicquel G2, Falvey H3
1Pharmerit International, Rotterdam, Netherlands, 2Glaukos Corporation, Paris, France, 3Glaukos Corp, San Clemente, CA, USA

OBJECTIVES: To estimate the cost-utility of two micro-bypass trabecular stents (MBTS) implantation versus standard of care (SOC) of pharmacotherapy in the French healthcare setting.

METHODS: A Markov model was designed to track progression of glaucoma through health states defined using Hodapp-Parrish-Anderson stages, mild, moderate, advanced, severe/blind, and death over a lifetime horizon. Reduction in intraocular pressure (IOP) and medication use due to MBTS and SOC were identified from randomized clinical trials and meta-analyzed. Transition probabilities were estimated using IOP-adjusted rate of decline in visual field (VF) loss. A 5% decline in relative treatment effect per year was assumed for extrapolation of efficacy beyond trial follow-up. Unit costs and resource use for France in 2018 were obtained from targeted literature reviews and expert advice. French claims data were acquired from MedicAM and used to estimate glaucoma medication costs with wastage, and medication persistence was extrapolated based on a recent French study. Probabilistic and one-way sensitivity analyses were conducted to estimate the impact of uncertainty on costs and quality-adjusted life years (QALYs).

RESULTS: The meta-analysis shows a relative reduction in medication use by 1.13 drugs per patient in combination with a relative reduction of IOP by 1.10 mmHg at 36 months for MBTS compared to SOC. These outcomes lead to an estimated health gain of 0.154 QALYs and cost increase of €735 per patient, over a lifetime, leading to an ICUR of €4,760 per QALY gained. Sensitivity analyses showed that results were robust to variations in model assumptions.

CONCLUSIONS: The cost of MBTS is partially offset by the decreased medication costs and lower rate of secondary procedures. Together with the expected quality of life gains, MBTS, such as iStent inject could be considered a cost-effective treatment option for patients with mild-to-moderate open-angle glaucoma in France.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PMD18

Topic

Clinical Outcomes, Economic Evaluation

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Relating Intermediate to Long-term Outcomes, Trial-Based Economic Evaluation

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×